.png){kind=logo}
This exclusive RAD session on Monday, July 14th at 2:00 PM ET featured Novo Nordisk. We explored one of the most important and often overlooked challenges in our space: managing high-cost claimants. Through real-world examples and case studies, we examined what’s working, what’s not, and where treatment innovations are emerging.
RAD Member Highlights:
-
Get early access to emerging strategies from a leading pharma innovator
-
Learn how to help clients think beyond GLP-1s and tackle under-the-radar cost drivers
-
Connect with peers in the RAD community during a live discussion
Additional resources
CCSCHEMO.com –look under resources
This is the group that worked with the Midwest business health coalition on the hemophilia toolkit; found here: Hemophilia Toolkit - Midwest Business Group on Health
CCSCHemo is now part of the National Bleeding Disorders Foundation, the largest patient advocacy group in the US.
National Bleeding Disorders Foundation, formerly NHF | National Bleeding Disorders Foundation
In the National Bleeding Disorders Foundation, one can find the Medical and Scientific Recommendations on Treatment in hemophilia and other bleeding disorders MASAC Treatment Guidelines for Blood and Bleeding Disorders | NBDF
If people are looking for additional guidelines, this is quite comprehensive from the World Federation of Hemophilia. US physicians were authors on this. Although published in 2020, updates are in process and Hemlibra/ Emicizumab is included in the 2020 guidelines.